Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTH125
- Development stage
- Preclinical
- Lead developer
- Connecta Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CTH125 is a preclinical-stage small molecule candidate developed by Connecta Therapeutics. It is part of the company's pipeline of neuroplasticity modulators designed to treat central nervous system (CNS) disorders, including neurodevelopmental and neurodegenerative conditions. While specific details regarding its molecular target and primary indication have not been extensively disclosed, it belongs to the same chemical series as the company's lead asset, CTH120, which targets the Rho GTPase pathway to restore synaptic function and dendritic spine morphology. CTH125 is currently in the discovery or early preclinical phase of development.
02
Targets
Rho family (Rho family GTPases)
Beyond the preview
Go deeper on CTH125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTH125.